Charts

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced it will release its fourth quarter and full year 2022 financial results before the market opens on Thursday, March 30, 2023. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, March 30, 2023.

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that the Company will participate in two upcoming investor conferences in February and March 2023.

Better Therapeutics Inc(NASDAQ: BTTX) announcedtopline resultsof the first-ever study evaluating the feasibility of ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced positive topline results of the first-ever study evaluating the feasibility of using a prescription digital therapeutic to reduce liver fat and improve liver disease biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that the compensation committee of Better Therapeutics’ board of directors approved the grant of a nonqualified stock option exercisable for 200,000 shares of Better Therapeutics’ common stock to Diane Gomez-Thinnes, Chief Commercial Officer, under the company’s 2022 Inducement Plan, effective on December 1, 2022 (Grant Date). The stock option was granted as an inducement material to Ms. Gomez-Thinnes becoming an employee of Better Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that Frank Karbe, Chief Executive Officer, and Mark Berman, MD, Chief Medical Officer, will participate in a virtual fireside chat at the BTIG Digital Health Forum on Monday, November 21, 2022, at 2:00 p.m. ET / 11:00 a.m. PT. Better Therapeutics management will be available for virtual one-on-one meetings with investors during the conference.

Chardan Capital raised PDS Biotechnology Corporation (NASDAQ: PDSB) price target from $15 to $16. . Chardan Capital analyst Geulah ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today reported financial results for the third quarter of 2022 and provided an update on progress toward achieving key corporate milestones.

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced it will release its third quarter 2022 financial results after the market closes on Monday, November 14, 2022. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on Monday, November 14, 2022.

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, announced today that Diane Gomez-Thinnes joined the company as Chief Commercial Officer starting October 26, 2022.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. The post Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced that the positive 90 day results from its pivotal trial for BT-001, a potentially first-of-its-kind digital therapeutic platform that is designed to use CBT to treat type 2 diabetes (T2D) in patients 18 years and older, have been published in the American Diabetes Association (ADA)-produced, peer reviewed journal Diabetes Care.

Better Therapeutics Inc(NASDAQ: BTTX) has submitted ade novoclassification requestto the FDA seeking approval ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced that it has submitted a de novo classification request to the U.S. Food and Drug Administration (FDA) seeking marketing authorization for BT-001, its potentially first-in-class digital therapeutic designed to use CBT to treat Type 2 Diabetes (T2D) in patients 18 years and older.

The Nasdaq 100 dropped by more than 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe, Chief Executive Officer, along with other members of the company’s management team, will participate in three upcoming investor conferences in September 2022.

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 72.8% to close at $2.16 on Monday as the stock continued to see ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! Let's get right into the biggest pre-market stock movers on Monday that traders will want to watch! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares rose 48.5% to $0.56 in pre-market trading. Kiromic Biopharma said the ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today reported financial results for the second quarter of 2022 and provided an update on progress toward achieving key corporate milestones.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Total Stock Market ETF (VTI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $244.41 per unit.

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will release its second quarter 2022 financial results before the market opens on Thursday, August 11, 2022. Management will host a conference call and webcast to provide a business update at 8:30 a.m. ET / 5:30 a.m. PT on Thursday, August 11, 2022.

Gainers MMTec, Inc. (NASDAQ: MTC) shares gained 390.6% to close at $7.85 on Tuesday amid volatility in nano-cap Chinese ...

Gainers Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 297.9% to $2.71 during Tuesday's regular session. ...

Gainers AMTD IDEA Group (NYSE: AMTD) shares jumped 284% to $8.00 after jumping 18% on Monday. The company owns 90%+ of AMTD ...

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around ...

Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is ...

Cyclerion Therapeutics (NASDAQ: CYCN) announced positive topline data from its clinical study of CY6463 for the treatment of ...

Gainers Athersys (NASDAQ:ATHX) stock rose 73.2% to $0.33 during Thursday's regular session. The current volume of ...

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 231% to $2.63 on news that the company will be acquired By Henry Crown ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Hydrogen stocks are climbing higher on Thursday thanks to news of Democrats reaching an agreement on climate change legislation. The post Why Are Hydrogen Stocks PLUG, FCEL, BE Heating Up Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” Cash Holders Could Get Hit Hard THIS FRIDAY

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Better Therapeutics (BTTX) stock is rocketing higher on Thursday as investors react to results from a Phase 2 clinical trial. The post Why Is Better Therapeutics (BTTX) Stock Up 27% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” Cash Holders Could Get Hit Hard THIS FRIDAY

Better Therapeutics (NASDAQ: BTTX) announced positive results from its pivotal clinical trial for BT-001, prescription digital ...

Better Therapeutics Inc(NASDAQ: BTTX)completed the pivotal clinical trial for BT-001, an investigational prescription ...

Gainers Better Therapeutics (NASDAQ:BTTX) shares moved upwards by 67.3% to $2.56 during Thursday's pre-market ...

Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the completion of the pivotal clinical trial for BT-001, an investigational first-in-class prescription digital therapeutic that is designed to use nCBT to treat type 2 diabetes (T2D).

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET to review the results from the pivotal clinical trial of BT-001 after 180 days of treatment for type 2 diabetes. Members of the Better Therapeutics management team will be joined by Marc Bonaca, MD, MPH, Professor of Medicine and Director of Vascular Research at University of Colorado.

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the publication of a manuscript detailing the study design and methodology for its pivotal clinical trial of BT-001 in adult patients with type 2 diabetes (T2D) in the medical journal, Clinical Cardiology. The study represents a first-in-class randomized, controlled clinical trial of a prescription digital therapeutic (PDT) for the treatment of T2D and is expected to support the filing of a de novo classification request with the U.S. Food and Drug Administration (FDA) in the third quarter of 2022. The company announced positive primary endpoint data for this trial in March of this year and expects to release secondary data in the third quarter of this year.

SAN FRANCISCO, July 11, 2022--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the publication of a manuscript detailing the study design and methodology for its pivotal clinical trial of BT-001 in adult patients with type 2 diabetes (T2D) in the medical journal, Clinical Cardiology. The study represents a first-in-class randomize

Gainers Aprea Therapeutics (NASDAQ:APRE) shares increased by 20.0% to $0.96 during Friday's pre-market session. The ...

U.S. crude oil futures traded higher this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. When ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While you don’t want to play with money you can’t afford to lose, these penny stocks might bring home the goods for the bold. The post 3 Penny Stocks That Have Huge Catalysts Ahead appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it ...

Gainers Omeros (NASDAQ:OMER) shares increased by 23.7% to $2.71 during Wednesday's regular session. As of 13:30 EST, ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Co-Founder and CEO, will participate in the Commercializing Prescription Digital Therapeutics panel at the Cowen 7th Annual FutureHealth Conference on Thursday, June 23, 2022 at 12:40 p.m. ET.

US gold futures traded higher this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders ...

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will participate in a webinar on Unlocking the Value of Digital Prescription Therapeutics hosted by Cowen to discuss the recently released promising pivotal clinical trial data for BT-001, its digital therapeutic platform for type 2 diabetes, and how BT-001 may be used in the current type 2 diabetes treatment paradigm.

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that the U.S. Patent and Trade Office (USPTO) has granted their first patent, granting twenty years of exclusivity for a number of key features core to the company’s digital therapeutics platform, designed to help treat cardiometabolic diseases through the delivery of digital behavioral therapy as a PDT.

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the company as President and Chief Executive Officer and serve as a member of the Board of Directors starting July 5th, 2022. Current CEO and company co-founder, Kevin Appelbaum, will continue to serve in that role until then.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips This week's list of potential short squeeze stocks from Fintel is certainly drawing attention, with some big names featured on the list. The post Short Squeeze Stocks: RDBX, BTTX and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur ...